16 withdrawn. 16 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Withdrawn 16 |
| Phase 2 | 4 | Withdrawn 4 |
Follow Congenital Abnormalities: new trials by email Literature Review of Congenital Abnormalities trials Research Report on Congenital Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution - Ehlers-Danlos Syndrome, Low Back Pain | Phase 3 | Withdrawn | Tulane University | 2026-10-05 | 2026-10-08 | |
| Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease Sildenafil, Placebos - Single-ventricle, Pulmonary Hypertension | Phase 3 | Withdrawn | University Hospital, Montpellier | 2023-06-01 | 2023-05-15 | |
| A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome RAD011 - Prader-Willi Syndrome | Phase 3 | Withdrawn | Radius Pharmaceuticals, Inc. | 2023-01-01 | 2022-10-06 | |
| A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) Tolvaptan (OPC-41061) - Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Phase 3 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-07-01 | 2025-12-24 | |
| Topical Everolimus in Patients With Tuberous Sclerosis Complex Everolimus, Placebo - Facial Angiofibromas | Phase 2 / Phase 3 | Withdrawn | Hospices Civils de Lyon | 2020-12-01 | 2021-05-03 | |
| The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial AVCN583601 (3% Cannabidiol cream) - Epidermolysis Bullosa, Pain | Phase 2 / Phase 3 | Withdrawn | Elena Pope | 2020-08-01 | 2021-06-18 | |
| Iatrogenic Atrial Septal Defect Study (iASD) atrial septal defect closure - Septal Defect, Atrial | Phase 3 | Withdrawn | Henry Ford Health System | 2020-05-06 | 2022-12-08 | |
| Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly Dactolisib, Placebo - Clinically Symptomatic Respiratory Illness | Phase 3 | Withdrawn | Restorbio Inc. | 2019-10-21 | 2019-11-22 | |
| Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury gases Nitric Oxide (gNO) - Acute Kidney Injury, Congenital Heart Disease | Phase 2 / Phase 3 | Withdrawn | Children's Hospital Medical Center, Cincinnati | 2019-10-20 | 2020-02-06 | |
| An Open-Label Study of DCCR Tablet in Patients With PWS DCCR - Prader-Willi Syndrome | Phase 3 | Withdrawn | Soleno Therapeutics, Inc. | 2019-10-01 | 2021-08-03 | |
| Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Chronocort®, Standard Care - Congenital Adrenal Hyperplasia | Phase 3 | Withdrawn | Neurocrine UK Limited | 2018-10-04 | 2026-09-14 | |
| Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients inhaled nitric oxide - Congenital Heart Disease, Fontan | Phase 3 | Withdrawn | University of California, San Francisco | 2012-06-01 | 2018-05-04 | |
| Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome Blood draw - Marfan Syndrome | Phase 3 | Withdrawn | Ann & Robert H Lurie Children's Hospital of Chicago | 2011-04-01 | 2016-02-05 | |
| Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia insulin glargine recombinant, therapeutic insulin - Hyperglycemia, Leukemia | Phase 3 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2009-05-01 | 2013-08-30 | |
| A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives Norgestimate-ethinyl estradiol, with or without folic acid - Neural Tube Defects, Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Phase 3 | Withdrawn | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2016-09-20 | ||
| Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) LDE225B, Vehicle - Basal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2017-05-05 |
Heart Defects, Congenital (3) · Prader-Willi Syndrome (2) · Acute Kidney Injury (1) · Adrenal Hyperplasia, Congenital (1) · Basal Cell Nevus Syndrome (1) · Carcinoma, Basal Cell (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Ehlers-Danlos Syndrome (1) · Epidermolysis Bullosa (1) · Heart Septal Defects, Atrial (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hyperglycemia (1) · Hypertension, Pulmonary (1) · Influenza, Human (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (10) · Cardiovascular Diseases (6) · Abnormalities, Multiple (5) · Cardiovascular Abnormalities (5) · Heart Diseases (5) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Nutritional and Metabolic Diseases (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Neoplasms (3) · Skin and Connective Tissue Diseases (3)
Blood Specimen Collection (1) · Dexamethasone (1) · Everolimus (1) · Glucose (1) · Hydrocortisone (1) · Insulin (1) · Insulin Glargine (1) · Lidocaine (1) · Moxifloxacin (1) · Prednisolone (1) · Prednisone (1) · Sildenafil Citrate (1) · Standard of Care (1) · Tolvaptan (1) · dactolisib (1)
Ann & Robert H Lurie Children's Hospital of Chicago (1) · Children's Hospital Medical Center, Cincinnati (1) · Elena Pope (1) · Henry Ford Health System (1) · Hospices Civils de Lyon (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Neurocrine UK Limited (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Radius Pharmaceuticals, Inc. (1) · Restorbio Inc. (1) · Soleno Therapeutics, Inc. (1) · Tulane University (1) · University Hospital, Montpellier (1) · University of California, San Francisco (1)
United States (5) · Canada (2) · Belgium (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Elena Pope, MD (1) · Jacques Courseault, MD (1) · Jeffery Meadows, MD (1) · Marvin Eng, MD (1) · Mecide Gharibo, MD (1) · Olga Sergeyeva, MD (1)
2018 (1), P30CA072720 (1)